Ryan Maynard

Ryan joined Foghorn Therapeutics as Chief Financial Officer in February 2026. He brings more than 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical and healthcare technology companies.

Prior to joining Foghorn, Ryan served as Chief Financial Officer at Cara Therapeutics, Inc., where he led financial strategy and strategic transactions, including the successful execution of a reverse merger with Tvardi Therapeutics and a $37.5 million non-dilutive royalty financing. He also provided executive leadership across commercial manufacturing and launch planning for KORSUVA^®.

Previously, Ryan served as Chief Financial Officer at Rigel Pharmaceuticals, LetsGetChecked Inc., and Blade Therapeutics. As a CFO, he has raised more than $1 billion through public and private financings and played a key role in the development, FDA approval, and commercial launch planning of TAVALISSE^®. He has extensive experience building strong relationships with healthcare-focused investors and scaling organizations through critical phases of growth.

Ryan holds a B.S. in Commerce with a focus in accounting from Santa Clara University. He currently serves on the board of Iovance Biotherapeutics, Inc.